See other companies on Welcome to the Jungle
PostEra
Machine learning for drug discovery
- 21-100 employees
- Healthcare
- B2B
- Machine Learning
- MedTech
- North End, Boston, MA
Jump to section
Company mission
To close the Design-Make-Test cycle of medicinal chemistry and bring more cures to patients.
Our take
Responding to the fact that developing cures for diseases has a high rate of failure and has long been time-consuming, PostEra developed Proton, a machine learning platform that allows the company to carry out faster drug discovery, find more optimized drug candidates, and ultimately better develop cures for patients.
The company has received impressive capital from top investors, which will be invested into developing its product.
PostEra also recently closed a $68M NIH partnership to prevent pandemics, and secured a $260M partnership with Pfizer, the latter of which uses Pfizer’s expertise and data with PostEra’s technology to advance drug discovery programs.
Steph
Company Specialist at Welcome to the Jungle
Funding (2 rounds)
Jan 2022
$24m
SERIES A
Mar 2020
$0.2m
SEED
Total funding: $24.2m
This company has top investors
Leadership
Aaron Morris
(CEO)Most recently served in Equities Trading (Event-Driven Quant) for Goldman Sachs.
Alpha Lee
(CSO)Recently was one of the Scientific co-founders of Byterat. Since 2017, has been a Faculty Member leading research in Machine Learning and Drug Discovery for the University of Cambridge.
Matt Robinson
(CTO)Previously did research in Biomolecular Simulation and Machine Learning for Drug Discovery at Yale University and University of Cambridge, before co-founding PostEra.